Patents Assigned to 4D MOLECULAR THERAPEUTICS INC.
-
Publication number: 20240131195Abstract: The present disclosure provides compositions and methods for the treatment of ocular diseases associated with angiogenesis, particularly wet age-related macular degeneration.Type: ApplicationFiled: October 5, 2023Publication date: April 25, 2024Applicant: 4D MOLECULAR THERAPEUTICS INC.Inventors: Christian BURNS, Melissa CALTON, Meredith LEONG, Paul SZYMANSKI
-
Publication number: 20240066145Abstract: Provided herein are variant adeno-associated virus (AAV) capsid proteins having one or more modifications in amino acid sequence relative to a parental AAV capsid protein, which, when present in an AAV virion, confer increased infectivity of one or more types of retinal cells as compared to the infectivity of the retinal cells by an AAV virion comprising the unmodified parental AAV capsid protein. Also provided are recombinant AAV virions and pharmaceutical compositions thereof comprising a variant AAV capsid protein as described herein, methods of making these rAAV capsid proteins and virions, and methods for using these rAAV capsid proteins and virions in research and clinical practice, for example in, e.g., the delivery of nucleic acid sequences to one or more cells of the retina for the treatment of retinal disorders and diseases.Type: ApplicationFiled: August 10, 2023Publication date: February 29, 2024Applicant: 4D MOLECULAR THERAPEUTICS INC.Inventors: David H. Kirn, Melissa Kotterman, David Schaffer
-
Publication number: 20240067987Abstract: The present disclosure provides a variant AAV capsid protein that confers tropism to lung cells and recombinant adeno-associated viruses comprising the variant A.AV and pharmaceutical compositions comprising same and their use in the delivery of heterologous nucleic acids to lung cells for the treatment of pulmonary disorders.Type: ApplicationFiled: September 15, 2023Publication date: February 29, 2024Applicant: 4D MOLECULAR THERAPEUTICS INC.Inventors: Melissa Kotterman, Peter Francis, Melissa Calton, Johnny Gonzales, Roxanne Croze, Christopher Schmitt
-
Publication number: 20240018498Abstract: The present disclosure provides codon optimized nucleotide sequences encoding hum n alpha-galactosidase A, vectors, and host cells comprising codon optimized alpha-galactosidase A sequences, and methods of treating disorders such as Fabry disease comprising administering to the subject a codon optimized sequence encoding human alpha-galactosidase A.Type: ApplicationFiled: September 8, 2023Publication date: January 18, 2024Applicant: 4D MOLECULAR THERAPEUTICS INC.Inventors: David H. KIRN, Melissa KOTTERMAN, Peter FRANCIS, David SCHAFFER, Paul SZYMANSKI, Kevin WHITTLESEY
-
Patent number: 11840704Abstract: Provided herein are variant adeno-associated virus (AAV) capsid proteins having one or more modifications in amino acid sequence relative to a parental AAV capsid protein, which, when present in an AAV virion, confer increased infectivity of one or more types of muscle cells as compared to the infectivity of the muscle cells by an AAV virion comprising the unmodified parental AAV capsid protein. Also provided are recombinant AAV virions and pharmaceutical compositions thereof comprising a variant AAV capsid protein as described herein, methods of making these rAAV capsid proteins and virions, and methods for using these rAAV capsid proteins and virions in research and in clinical practice, for example in, e.g., the delivery of nucleic acid sequences to one or more muscle cells for the treatment of muscle disorders and diseases.Type: GrantFiled: December 21, 2022Date of Patent: December 12, 2023Assignee: 4D Molecular Therapeutics Inc.Inventors: David H. Kirn, Melissa Kotterman, David Schaffer
-
Patent number: 11807868Abstract: The present disclosure provides a variant AAV capsid protein that confers tropism to lung cells and recombinant adeno-associated viruses comprising the variant AAV and pharmaceutical compositions comprising same and their use in the delivery of heterologous nucleic acids to lung cells for the treatment of pulmonary disorders.Type: GrantFiled: October 6, 2022Date of Patent: November 7, 2023Assignee: 4D Molecular Therapeutics Inc.Inventors: Melissa Kotterman, Peter Francis, Melissa Calton, Johnny Gonzales, Roxanne Croze, Christopher Schmitt
-
Publication number: 20230340042Abstract: The present disclosure provides codon optimized RPGRorf15 sequences, vectors, and host cells comprising codon optimized RPGRorf15 sequences, and methods of treating retinal disorders such as XLRP comprising administering to the subject a codon optimized RPGRorf15 sequence.Type: ApplicationFiled: August 30, 2021Publication date: October 26, 2023Applicant: 4D MOLECULAR THERAPEUTICS INC.Inventors: David H. KIRN, Melissa A. KOTTERMAN, David SCHAFFER, Peter FRANCIS
-
Patent number: 11766487Abstract: Provided herein are variant adeno-associated virus (AAV) capsid proteins having one or more modifications in amino acid sequence relative to a parental AAV capsid protein, which, when present in an AAV virion, confer increased infectivity of one or more types of retinal cells as compared to the infectivity of the retinal cells by an AAV virion comprising the unmodified parental AAV capsid protein. Also provided are recombinant AAV virions and pharmaceutical compositions thereof comprising a variant AAV capsid protein as described herein, methods of making these rAAV capsid proteins and virions, and methods for using these rAAV capsid proteins and virions in research and clinical practice, for example in, e.g., the delivery of nucleic acid sequences to one or more cells of the retina for the treatment of retinal disorders and diseases.Type: GrantFiled: December 21, 2022Date of Patent: September 26, 2023Assignee: 4D Molecular Therapeutics Inc.Inventors: David H. Kirn, Melissa Kotterman, David Schaffer
-
Patent number: 11766489Abstract: Provided herein are variant adeno-associated virus (AAV) capsid proteins having one or more modifications in amino acid sequence relative to a parental AAV capsid protein, which, when present in an AAV virion, confer increased infectivity of one or more types of retinal cells as compared to the infectivity of the retinal cells by an AAV virion comprising the unmodified parental AAV capsid protein. Also provided are recombinant AAV virions and pharmaceutical compositions thereof comprising a variant AAV capsid protein as described herein, methods of making these rAAV capsid proteins and virions, and methods for using these rAAV capsid proteins and virions in research and in clinical practice, for example in, e.g., the delivery of nucleic acid sequences to one or more cells of the retina for the treatment of retinal disorders and diseases.Type: GrantFiled: November 26, 2018Date of Patent: September 26, 2023Assignee: 4D Molecular Therapeutics, Inc.Inventors: David H. Kirn, Melissa Kotterman, David Schaffer, Paul Szymanski, Peter Francis
-
Publication number: 20230279435Abstract: Provided herein are variant adeno-associated virus (AAV) capsid proteins having one or more modifications in amino acid sequence relative to a parental AAV capsid protein, which, when present in an AAV virion, confer increased infectivity of one or more types of muscle cells as compared to the infectivity of the muscle cells by an AAV virion comprising the unmodified parental AAV capsid protein. Also provided are recombinant AAV virions and pharmaceutical compositions thereof comprising a variant AAV capsid protein as described herein, methods of making these rAAV capsid proteins and virions, and methods for using these rAAV capsid proteins and virions in research and in clinical practice, for example in, e.g., the delivery of nucleic acid sequences to one or more muscle cells for the treatment of muscle disorders and diseases.Type: ApplicationFiled: December 21, 2022Publication date: September 7, 2023Applicant: 4D MOLECULAR THERAPEUTICS INC.Inventors: David H. Kirn, Melissa Kotterman, David Schaffer
-
Publication number: 20230257772Abstract: The present disclosure provides a variant AAV capsid protein that confers tropism to lung cells and recombinant adeno-associated viruses comprising the variant AAV and pharmaceutical compositions comprising same and their use in the delivery of heterologous nucleic acids to lung cells for the treatment of pulmonary disorders.Type: ApplicationFiled: October 6, 2022Publication date: August 17, 2023Applicant: 4D Molecular Therapeutics Inc.Inventors: Melissa Kotterman, Peter Francis, Melissa Calton, Johnny Gonzales, Roxanne Croze, Christopher Schmitt
-
Publication number: 20230211013Abstract: Provided herein are variant adeno-associated virus (AAV) capsid proteins having one or more modifications in amino acid sequence relative to a parental AAV capsid protein, which, when present in an AAV virion, confer increased infectivity of one or more types of retinal cells as compared to the infectivity of the retinal cells by an AAV virion comprising the unmodified parental AAV capsid protein. Also provided are recombinant AAV virions and pharmaceutical compositions thereof comprising a variant AAV capsid protein as described herein, methods of making these rAAV capsid proteins and virions, and methods for using these rAAV capsid proteins and virions in research and clinical practice, for example in, e.g., the delivery of nucleic acid sequences to one or more cells of the retina for the treatment of retinal disorders and diseases.Type: ApplicationFiled: December 21, 2022Publication date: July 6, 2023Applicant: 4D MOLECULAR THERAPEUTICS INC.Inventors: David H. Kirn, Melissa Kotterman, David Schaffer
-
Publication number: 20230190964Abstract: The present disclosure provides codon optimized nucleotide sequences encoding human alpha-galactosidase A, vectors, and host cells comprising codon optimized alpha-galactosidase A sequences, and methods of treating disorders such as Fabry disease comprising administering to the subject a codon optimized sequence encoding human alpha-galactosidase A.Type: ApplicationFiled: October 11, 2022Publication date: June 22, 2023Applicant: 4D MOLECULAR THERAPEUTICS INC.Inventors: David H. Kirn, Melissa Kotterman, Peter Francis, David Schaffer, Paul Szymanski, Kevin Whittlesey
-
Publication number: 20230158172Abstract: The present disclosure provides codon optimized nucleotide sequences encoding human REP1, vectors, and host cells comprising codon optimized REP1 sequences, and methods of treating retinal disorders such as choroideremia comprising administering to the subject a codon optimized sequence encoding human REP1.Type: ApplicationFiled: November 4, 2022Publication date: May 25, 2023Applicant: 4D MOLECULAR THERAPEUTICS INC.Inventors: David H. Kirn, Melissa A. Kotterman, Peter Francis
-
Patent number: 11576983Abstract: Provided herein are variant adeno-associated virus (AAV) capsid proteins having one or more modifications in amino acid sequence relative to a parental AAV capsid protein, which, when present in an AAV virion, confer increased infectivity of one or more types of retinal cells as compared to the infectivity of the retinal cells by an AAV virion comprising the unmodified parental AAV capsid protein. Also provided are recombinant AAV virions and pharmaceutical compositions thereof comprising a variant AAV capsid protein as described herein, methods of making these rAAV capsid proteins and virions, and methods for using these rAAV capsid proteins and virions in research and clinical practice, for example in, e.g., the delivery of nucleic acid sequences to one or more ceils of the retina for the treatment of retinal disorders and diseases.Type: GrantFiled: May 17, 2022Date of Patent: February 14, 2023Assignee: 4D Molecular Therapeutics Inc.Inventors: David H. Kirn, Melissa Kotterman, David Schaffer
-
Publication number: 20230001018Abstract: Provided herein are variant adeno-associated virus (AAV) capsid proteins having one or more modifications in amino acid sequence relative to a parental AAV capsid protein, which, when present in an AAV virion, confer increased infectivity of one or more types of retinal cells as compared to the infectivity of the retinal cells by an AAV virion comprising the unmodified parental AAV capsid protein. Also provided are recombinant AAV virions and pharmaceutical compositions thereof comprising a variant AAV capsid protein as described herein, methods of making these rAAV capsid proteins and virions, and methods for using these rAAV capsid proteins and virions in research and clinical practice, for example in, e.g., the delivery of nucleic acid sequences to one or more ceils of the retina for the treatment of retinal disorders and diseases.Type: ApplicationFiled: May 17, 2022Publication date: January 5, 2023Applicant: 4D MOLECULAR THERAPEUTICS INC.Inventors: David H. KIRN, Melissa KOTTERMAN, David SCHAFFER
-
Patent number: 11524081Abstract: The present disclosure provides codon optimized nucleotide sequences encoding human REP1, vectors, and host cells comprising codon optimized REP1 sequences, and methods of treating retinal disorders such as choroideremia comprising administering to the subject a codon optimized sequence encoding human REP1.Type: GrantFiled: May 9, 2022Date of Patent: December 13, 2022Assignee: 4D Molecular Therapeutics Inc.Inventors: David H. Kirn, Melissa A. Kotterman, Peter Francis
-
Patent number: 11499166Abstract: The present disclosure provides a variant AAV capsid protein that confers tropism to lung cells and recombinant adeno-associated viruses comprising the variant AAV and pharmaceutical compositions comprising same and their use in the delivery of heterologous nucleic acids to lung cells for the treatment of pulmonary disorders.Type: GrantFiled: April 26, 2021Date of Patent: November 15, 2022Assignee: 4D Molecular Therapeutics Inc.Inventors: Melissa Kotterman, Peter Francis, Melissa Calton, Johnny Gonzales, Roxanne Croze, Christopher Schmitt
-
Publication number: 20220265860Abstract: The present disclosure provides codon optimized nucleotide sequences encoding human REP1, vectors, and host cells comprising codon optimized REP1 sequences, and methods of treating retinal disorders such as choroideremia comprising administering to the subject a codon optimized sequence encoding human REP1.Type: ApplicationFiled: May 9, 2022Publication date: August 25, 2022Applicant: 4D MOLECULAR THERAPEUTICS INC.Inventors: David H. KIRN, Melissa A. KOTTERMAN, Peter FRANCIS
-
Patent number: 11419949Abstract: Provided herein are variant adeno-associated virus (AAV) capsid proteins having one or more modifications in amino acid sequence relative to a parental AAV capsid protein, which, when present in an AAV virion, confer increased infectivity of one or more types of retinal cells as compared to the infectivity of the retinal cells by an AAV virion comprising the unmodified parental AAV capsid protein. Also provided are recombinant AAV virions and pharmaceutical compositions thereof comprising a variant AAV capsid protein as described herein, methods of making these rAAV capsid proteins and virions, and methods for using these rAAV capsid proteins and virions in research and in clinical practice, for example in, e.g., the delivery of nucleic acid sequences to one or more cells of the retina for the treatment of retinal disorders and diseases.Type: GrantFiled: January 29, 2021Date of Patent: August 23, 2022Assignee: 4D Molecular Therapeutics Inc.Inventors: David H. Kirn, Melissa Kotterman, David Schaffer